ASH 2022 | Treatment options for first-line & R/R wAIHA and unmet needs in this field
Irina Murakhovskaya, MD, Montefiore Medical Center, Albert Einstein College of Medicine, New York City, NY, outlines currently available treatment options for patients with warm autoimmune hemolytic anemia (wAIHA), including steroids in the first-line setting, and rituximab, immunosuppressive agents, and splenectomy in later lines of treatment. Dr Murakhovskaya explains that these treatments are associated with significant toxicity, and it is thus important to develop novel strategies for R/R patients, as well as to reduce the duration of exposure to steroids. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Incyte: Research Funding; Alexion: Research Funding; Annexon: Research Funding; Kezar: Research Funding; Rigel: Consultancy, Research Funding; Sanofi: Consultancy, Research Funding; Novartis: Consultancy, Research Funding.
